Histone deacetylase inhibitors (HDAC-Is), including for instance, Vorinostat and Panobinostat represent HDAC inhibitors that would therefore elicit a potential anti-tumor effect acting as epigenetic-targeting agents; and their activity has been also evaluated within the context of MM [97]. The gene discussed is HDAC9; the disease is Miyoshi myopathy.